National Cancer Institute (NCI)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Cancer Institute (NCI) sits in the top decile of US sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count).
National Cancer Institute (NCI): 3,257 sponsored US clinical trials, 326 recruiting.
National Cancer Institute (NCI) sponsors 3,257 registered US clinical trials on ClinicalTrials.gov, 326 of them currently recruiting, and 2,051 completed. 193 of these trials are in Phase 3-4 (later-stage) and 2,628 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignant Solid Neoplasm, with 67 trials.
Top-decile sponsor footprint
National Cancer Institute (NCI) ranks in the top decile of sponsors by registered trial count (#1 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
3,257 total, page 39 of 66
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00436501
Pazopanib in Treating Patients With Newly Diagnosed or Locally and/or Regionally Recurrent Breast Cancer That Can Be Removed By Surgery
NCT00450879
Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00445549
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
NCT00354107
Sorafenib in Treating Patients With Advanced Solid Tumors
NCT00436579
Aflibercept for Relapsed Multiple Myeloma
NCT00437034
3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
NCT00288093
Tabectedin to Treat Children and Adolescents With Cancer
NCT01453283
Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer
NCT00408694
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
NCT00436215
A Phase I Trial of Nelfinavir (Viracept ) in Adults With Solid Tumors
NCT01445106
Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors
NCT01445288
HGS-ETR2 to Treat Children With Solid Tumors
NCT00428272
Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
NCT00433576
3-AP in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00390052
Eribulin Mesylate and Cisplatin in Treating Patients With Advanced Solid Tumors
NCT00415324
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma
NCT00436605
Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer
NCT00416793
Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
NCT00445341
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
NCT00416598
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
NCT00436436
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
NCT00390325
Diindolylmethane in Healthy Volunteers
NCT00392652
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
NCT00408902
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
NCT00397787
Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma
NCT00410605
Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
NCT00337077
E7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung Cancer
NCT00400829
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium
NCT00407485
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
NCT00397878
AZD2171 to Treat Prostate Cancer
NCT00436956
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
NCT00410904
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus
NCT00378911
Lycopene in Healthy Male Participants
NCT00450957
Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases
NCT00390468
Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00407966
Sunitinib in Treating Young Patients With Refractory Solid Tumors
NCT00387920
Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes
NCT00393029
Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
NCT00365209
Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive
NCT00390455
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
NCT00267865
Data Analysis for 04-C-0234 Tenofovir Disoproxil Fumarate Salvage Therapy in HIV-Infected Children and a Study of Its Effect on Bone Metabolism
NCT01361165
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00409565
Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma
NCT00390234
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00377104
Bevacizumab and Irinotecan to Treat Brain Tumors
NCT00393094
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00383565
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
NCT00387426
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
NCT00381641
Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer
NCT00369122
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1199 |
| Phase 2 | 1429 |
| Phase 3 | 193 |
Therapeutic Areas
What is open in the National Cancer Institute (NCI) pipeline
326 recruiting of 3,257 indexed (10% open); 2,051 completed (63%).
Phase mix: 193 late (III/IV) vs 2,628 early (I/II) (early-phase heavy).
Top condition: Advanced Malignant Solid Neoplasm (67 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.